Rhythm Pharmaceuticals (RYTM) PT Raised to $176 at Citizens on Imcivree Growth Potential
Tweet Send to a Friend
Citizens analyst Jonathan Wolleben raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $176.00 (from $167.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
